E-viri
Recenzirano
Odprti dostop
-
Yi, Zong‐Bi; Yu, Pei; Zhang, Su; Wang, Wen‐Na; Han, Yi‐Qun; Ouyang, Qu‐Chang; Yan, Min; Wang, Xiao‐Jia; Hu, Xi‐Chun; Jiang, Ze‐Fei; Huang, Tao; Tong, Zhong‐Sheng; Wang, Shu‐Sen; Yin, Yong‐Mei; Li, Hui; Yang, Run‐Xiang; Yang, Hua‐Wei; Teng, Yue‐E; Sun, Tao; Cai, Li; Li, Hong‐Yuan; Chen, Xi; He, Jian‐Jun; Liu, Xin‐Lan; Yang, Shun‐E; Wang, Jia‐Yu; Fan, Jin‐Hu; Qiao, You‐Lin; Xu, Bing‐He
International journal of cancer, 1 February 2021, 2021-Feb-01, 2021-02-00, 20210201, Letnik: 148, Številka: 3Journal Article
Although receptor status including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) of the primary breast tumors was related to the prognosis of breast cancer patients, little information is yet available on whether patient management and survival are impacted by receptor conversion in breast cancer metastases. Using data from the nation‐wide multicenter clinical epidemiology study of advanced breast cancer in China (NCT03047889), we report the situation of retesting ER, PR and HER2 status for breast cancer metastases and evaluate the patient management and prognostic value of receptor conversion. In total, 3295 patients were analyzed and 1583 (48.0%) patients retesting receptor status for metastasis. Discordance in one or more receptors between the primary and the metastatic biopsy was found in 37.7% of women. Patients who remained hormone receptor (HR) positive in their metastases had similar progression‐free survival of first‐line and second‐line treatment compared to patients with HR conversion (P > .05). In multivariate analysis, patients who showed ER conversion from negative to positive had longer disease‐free survival (DFS) than patients who remained negative in their metastases (hazard ratio, 2.05; 95% confidence interval CI, 1.45‐2.90; P < .001). Patients with PR remained positive and had longer DFS than patients with PR conversion from negative to positive (hazard ratio, 0.56; 95% CI, 0.38‐0.83; P = .004). Patients with PR conversion have shorter overall survival than patients with PR remained positive or negative (P = .016 and P = .041, respectively). Our findings showed that the receptors' conversions were common in metastatic breast cancer, and the conversion impacted the survival. What's new? Tumor metastasis is still the main cause of breast cancer mortality. Treatment of metastatic tumors is often based on the hormone receptor and human epidermal growth factor receptor 2 status of the primary tumor. However, as many as a third of patients with metastases have altered receptor status. Does this receptor conversion affect prognosis? In this large Chinese study, the authors found that, in many cases, the answer is yes. These results indicate that it is clinically important to biopsy distant metastases and assess receptor status whenever possible and to use these results to guide treatment.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.